Literature DB >> 14978290

Excess radiation absorbed doses from non-optimised radioiodine treatment of hyperthyroidism.

Helene Jönsson1, Sören Mattsson.   

Abstract

Radioiodine therapy is often the method of choice for treatment of hyperthyroidism because it is considered safe, is relatively inexpensive, and is convenient for the patient and except for occasional hypothyroidism, almost without side effects. Even though radioiodine treatment has been performed for over 50 years, the method of treatment differs from country to country and even from hospital to hospital within the same country. To illuminate such differences 187 radioiodine treatments for Graves' disease at Malmö University Hospital in Sweden have been analysed. Comparative dose calculations were carried out assuming that the individual patients had also been treated according to a number of other protocols in current use. The results show that the protocol used for calculating the administered activity in radioiodine therapy is far from optimised in many hospitals. Following the protocols where the absorbed dose to the thyroid is calculated without any uptake measurements after administration of a test activity, most of the patients were treated with an unnecessarily high activity, as a mean factor of 2.5 times too high and in individual patients up to eight times too high, leading to an unnecessary radiation exposure both for the patient, the family and the public. This is not in accordance with generally accepted radiation protection principles. Using higher activity than necessary will also prolong the patient's stay at the hospital and thus increase the costs for the care. Unnecessarily high activity will also necessitate more long-lasting radiation protection restriction relative to family members when the patient is back home.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14978290     DOI: 10.1093/rpd/nch013

Source DB:  PubMed          Journal:  Radiat Prot Dosimetry        ISSN: 0144-8420            Impact factor:   0.972


  4 in total

1.  Improved Patient Dosimetry at Radioiodine Therapy by Combining the ICRP Compartment Model and the EANM Pre-Therapeutic Standard Procedure for Benign Thyroid Diseases.

Authors:  Martin Andersson; Sören Mattsson
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-12       Impact factor: 5.555

2.  Evaluation of the cytogenetic effects of (131)I preceded by recombinant human thyrotropin (rhTSH) in peripheral lymphocytes of Wistar rats.

Authors:  Márcia Augusta da Silva; Maria Inês Calil Cury Guimarães; Hélio Yoriyaz; Maria Teresa Carvalho Pinto Ribela; Carlos Alberto Buchpiguel; Paolo Bartolini; Kayo Okazaki
Journal:  Radiat Environ Biophys       Date:  2008-08-19       Impact factor: 1.925

3.  Gender differences in estimating I-131 thyroid uptake from Tc-99m thyroid uptake for benign thyroid disease.

Authors:  Amna Al-Jabri; Jennie Cooke; Seán Cournane; Marie-Louise Healy
Journal:  Br J Radiol       Date:  2020-12-11       Impact factor: 3.039

4.  Variations in the practice of molecular radiotherapy and implementation of dosimetry: results from a European survey.

Authors:  Katarina Sjögreen Gleisner; Emiliano Spezi; Pavel Solny; Pablo Minguez Gabina; Francesco Cicone; Caroline Stokke; Carlo Chiesa; Maria Paphiti; Boudewijn Brans; Mattias Sandström; Jill Tipping; Mark Konijnenberg; Glenn Flux
Journal:  EJNMMI Phys       Date:  2017-12-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.